| abstract |
FIELD: chemistry.SUBSTANCE: invention relates to a new compound of formula (I) or a pharmaceutically acceptable salt thereof. In formula (I)Q is 6-member heteroaryl containing one or two heteroatoms selected from N; W is selected from N and CН; Z is selected from N and CR; Ris selected from heterocyclyl-Calkyl, where heterocyclyl is 6–12-member mono- or bicyclic ring containing one or two nitrogen atoms or one or two nitrogen atoms and one oxygen atom, and alkyl and heterocyclyl are unsubstituted or substituted with at least one substitute, such as one, two, three or four substitutes independently selected from R; each Ris hydrogen; each Ris independently selected from hydrogen and Calkyl, where alkyl is unsubstituted or substituted with one, two, three or four substitutes independently selected from R; or two Rtogether with carbon atoms, to which they are bonded, form 3–7-member cyclic ring not containing additional heteroatoms and optionally substituted with 1, 2 or 3 groups R; Ris selected from hydrogen and halogen; each Ris hydrogen; each Ris independently selected from hydrogen and fluorine; each Ris independently selected from Calkyl, 6-member heterocyclyl containing two nitrogen atoms, halogen, -NRRand -OR, where alkyl and heterocyclyl are unsubstituted or substituted with at least one substitute, such as one, two, three or four substitutes independently selected from R; each Rand each Rare independently selected from hydrogen and Calkyl; Ris independently selected from Calkyl; m is 2 or 3; n is selected from 0, 1 and 2; p is selected from 0, 1, 2 and 3; q is selected from 1, 2 and 3.EFFECT: compounds have cyclin-dependent kinase 4/6 (CDK4/6) inhibitor properties and can be used for treating CDK4/6 related diseases, for example, for treating proliferative diseases.23 cl, 6 tbl, 169 ex |